BofA Finance LLC has filed a preliminary pricing supplement for its Auto-Callable Enhanced Return Notes, which are linked to the Nasdaq-100 and Russell 2000 indices. This filing, dated November 12, 2026, is significant as it indicates the company's ongoing efforts to diversify its financial products and enhance investor engagement.
BofA Finance LLC, categorized under National Commercial Banks (SIC: 6021), operates under the umbrella of Bank of America Corporation. The company has been active in the capital markets, as evidenced by its recent filings, including multiple 424B2 forms filed on November 13, 2026. The notes are expected to provide investors with returns based on the performance of the linked indices, reflecting a strategic move to cater to investor demand for innovative financial products.
The filing states, "This pricing supplement, which is not complete and may be changed, relates to an effective Registration Statement under the Securities Act of 1933." The notes are described as being due on December 5, 2029, and are expected to price on November 30, 2026. They will be issued in minimum denominations of $1,000.
This offering may affect a wide range of stakeholders, including investors seeking exposure to equity markets through structured products. The notes are designed to provide potential returns based on the performance of the Nasdaq-100 and Russell 2000 indices, but they also carry risks, including exposure to declines in the value of the underlying indices.
As for what’s next, the filing indicates that the pricing of the notes is expected to occur on November 30, 2026, with the issuance following shortly thereafter on December 3, 2026. This timeline suggests that BofA Finance LLC is moving quickly to capitalize on market conditions and investor interest.
Read Next
Dominion Energy announces $1.2 billion senior notes issuance
Lakefront Biotherapeutics Launches €50 Million Share Buyback
Coca-Cola Europacific Partners Announces Share Buyback Details
Zenta Group announces $6.47 million at-the-market offering
MapLight Therapeutics Enters $100 Million Sales Agreement
Cyabra, Inc. Secures $15.6 Million in Private Placement










